IP Library Granted Patent US 10,300,063
Granted Patent B2
US 10,300,063 · App. 15/108,810 · Granted May 28, 2019

Pharmaceutical composition not containing antioxidant and preparation method therefor

Inventors: Joong-Woong Cho (Daejeon, KR); Gyeong-Hae Kim (Daejeon, KR); Min-Hyo Seo (Daejeon, KR); Sa-Won Lee (Daejeon, KR)
Assignee: SAMYANG BIOPHARMACEUTICALS CORPORATION
A61K31/519A61K9/08A61K9/19A61K47/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,300,063
App. No.
15/108,810
Granted
May 28, 2019
Kind
B2
Abstract

Provided are a composition containing an unstable drug against oxidation like pemetrexed with improved stability and a preparation method thereof, by removing oxygen during the preparation without use of an antioxidant. The method is readily applicable for manufacturing by freezing and degassing in a sealed chamber, and can provide formulations with significantly increased stability for the unstable drug against oxidation.

Claims (13)

1. A method of preparing an antioxidant-free pharmaceutical composition, comprising:

(a) preparing an antioxidant-free solution with dissolved oxygen comprising pemetrexed or a pharmaceutically acceptable salt thereof, and an aqueous solvent in a container;

(b) freezing the antioxidant-free solution in the container to produce a frozen product; and

(c) degassing the frozen product under a pressure of 2,000 mTorr or lower to obtain a degassed and frozen product,

wherein the degassed and frozen product comprises 95 to 100 parts by weight of the solvent per 100 parts by weight of the solvent contained in the solution of step (a), and

the steps of (b) and (c) are performed at a temperature of −20° C. or tower in a sealed chamber.

2. The method of claim 1 , wherein the degassing in step (c) is performed to have a concentration of the dissolved oxygen to be 1.5 ppm or lower.

3. The method of claim 1 , wherein the degassing in step (c) is performed for 12 hours or shorter.

4. The method of claim 1 , wherein the solution further comprises at least one selected from the group consisting of (i) pharmaceutically acceptable excipients excluding antioxidants and (ii) pH adjusting agents.

5. The method of claim 4 , wherein the excipient is mannitol, or the pH adjusting agent is hydrochloric acid, sodium hydroxide, or a mixture thereof.

6. The method of claim 1 , wherein the method further comprises a step of sealing the container or a step of filling the container with nitrogen followed by sealing, after step (c).

7. The method of claim 1 , wherein the method further comprises thawing the degassed and frozen product, after step (c).

8. The method of claim 6 , wherein the method further comprises thawing the degassed and frozen product, after the sealing the container.

Assignments (2)
MERGER Recorded Nov 3, 2021
From: SAMYANG BIOPHARMACEUTICALS CORPORATION
To: SAMYANG HOLDINGS CORPORATION
Reel/Frame 058013/0766 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2016
From: CHO, JOONG-WOONG; KIM, GYEONG-HAE; SEO, MIN-HYO; LEE, SA-WON
To: SAMYANG BIOPHARMACEUTICALS CORPORATION
Reel/Frame 039037/0607 →
Priority Claims (1)
KR 10-2013-0167677 · Dec 30, 2013 · national
Continuity (1)
Related Publication 20160317539A1 · Nov 3, 2016